Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.

摘要: Surgical cure of glioblastomas is virtually impossible and their clinical course mainly determined by the biologic behavior tumor cells response to radiation chemotherapy. We investigated whether temozolomide (TMZ) chemotherapy differs in subsets malignant defined genetic lesions. Eighty patients with newly diagnosed glioblastoma were analyzed comparative genomic hybridization loss heterozygosity. All underwent radical resection. Fifty received TMZ after radiotherapy (TMZ group) 30 alone (RT group). The most common aberrations detected gains parts chromosome 7 losses 10q, 9p, or 13q. spectrum did not differ between RT groups. Patients treated showed significantly better survival than (19.5 vs 9.3 months). Genomic deletions on chromosomes 9 10 are typical for associated poor prognosis. However, these benefited from univariate analysis. In multivariate analysis, this effect was pronounced 9p deletion elderly 10q deletions, respectively. This study demonstrates that molecular cytogenetic analyses potentially predict responses glioblastomas.